Audit: QRS - Magnesium Stearate for Health & Longevity

Audit conducted on 26/08/2026 09:23 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every span traced to ER text: protocol cells to ER lines 300/306/308/310/325/351, benefit and risk items to the ER sub-section headings, gates to ER lines 264–280, monitoring table to ER lines 379–386, qualitative items to ER lines 390–394.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No half-life applies”, “None applies”, “Neither applies”, “Irrelevant in isolation” all mirror the ER’s own hedged formulations.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	At-a-glance “does not raise cholesterol” and “genetic-damage testing came back clean” match the ER Conclusion at the same strength; contraindications retain “unless a documented vegetable-source product is used”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid” list, Key Interactions only from the ER interaction bullets, risks only from ER Potential Risks & Side Effects.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT identifiers, or brand names (Thorne, Pure Encapsulations, Designs for Health) carried into the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, deflationary register, including its British spellings (“signalling”, “optimising”, “Normalised”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantities, ranges, and tiers throughout; framing lets the reader size the question rather than fear it.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive throughout, e.g. “Timing follows the active ingredient’s own requirement” rather than an instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring cadence describes what is done in practice; no directives to the reader.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “should”, “recommend”, or “advise” in the document’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address in any populated span.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Biomarkers spelled out in full (“Thyroid-Stimulating Hormone”, “Estimated Glomerular Filtration Rate”); “water-repelling film” style plain phrasing carried over from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lines are semicolon-joined single lines; gate items stripped to the key fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed across header, at-a-glance, protocol, gates, cards.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framed around the multi-supplement user: “a heavy supplement routine”, “a fifteen-capsule daily routine”.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Elimination-and-rechallenge window, daily symptom scoring, and post-switch retesting all presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Assumes a large daily unit count and formulation-level awareness, not casual use.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance closes on cumulative load from a large stack — the point where this audience’s exposure diverges from the general population’s.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the title carries “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Uses “capsule”, “tablet”, “excipient”, “dosage form”, “hypersensitivity”; “capsule stack” is the ER’s own term.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings byte-identical to the template (lines 440, 477, 519, 539, 549, 567, 586, 590–592, 694).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template span names present; marker_# and qualitative_item_# rows correctly expanded to 8 and 5 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows only content substitution inside addressed spans and repeated table/list rows; CSS, footer, and the website="…" spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	The only empty ER sections are tiered benefit/risk levels, which are governed by the more specific items 12.5 and 13.5; the ER supplies no empty-state phrasing for Benefits “Low”.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard exposure level”, “Best time of day”, “Single versus split dosing”, “Expected half-life”, “Time to effect”, “Lifelong versus short-term” all verbatim from the ER bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No invented labels; biomarker names match the ER table column verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji anywhere; the ER’s “⚠️ Conflicted” markers on two headings were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section condensed to the minimum the checklist permits: single-line tier summaries, gate items stripped to the key fact, monitoring “why” cells one clause each.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” line 3, closing “—” line 13; the preceding title line is permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value repeated in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: magnesium_stearate_2026-0826-0709_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: 2026-0826-0915.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk exactly.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Magnesium Stearate for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Magnesium Stearate for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/26/2026”, matching qrs_creation_date 2026-0826-0915.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” list was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all four Conclusion paragraphs (ER lines 414–418) into one passage.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Not-taken-for-an-effect (ER 414), cholesterol-neutral fat (416), food supplies far more (416), clean genotoxicity (416), one allergic case (416), cumulative-load uncertainty (418).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“genetic-damage testing” replaces genotoxicity; no acronyms, no clinical-register vocabulary.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results; “far more” replaces the ER’s mg figures.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All three items map to ER lines 278–280.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All three of the ER’s “Populations who should avoid Magnesium Stearate” bullets are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–544, three <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	“— absolute contraindication” stripped from item 1; “, since bovine and porcine tallow remain common feedstocks” stripped from item 3; the immunoglobulin E mechanism gloss stripped from item 2.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The clinical-presentation qualifier “(hives or angioedema)” is preserved, trimmed only of its plain-language gloss.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication bullets.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names three such populations and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map to ER lines 264–274.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All six ER interaction bullets present; no overlap with the three contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 552–557, six <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER action verdict and rationale sentence (“Caution, monitor. The gap between…”, “No action needed. …”) stripped; only the bold label survives.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All six drug/example lists preserved; only the trailing glosses (“which the body converts before they act”, “such as magnesium hydroxide and magnesium oxide”) trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names six interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol lines 300, 306, 310.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Exposure level, timing, and single-versus-split dosing are the three actionable bullets; the remaining ER bullets are modifier or background entries.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated from ER text; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Half-life (ER 308), time to effect (ER 351), lifelong versus short-term (ER 325).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The ER attaches no benefit magnitude to any time aspect, since there is no therapeutic effect; the standard pharmacokinetic-to-duration ordering is retained.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; sub-lines condensed from ER lines 308, 351, 325.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (ER line 351), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Items map to the ER benefit sub-headings at lines 152, 160, 170, 174, 178.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 521, 524, 527, 530.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a bare list of the ER’s own benefit names; no magnitude text, PMIDs, or trial detail carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER’s “Low 🟩” tier is empty and [benefits_low] carries style="display: none" with an empty item (line 527).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Items map to the ER risk sub-headings at lines 210, 216, 224, 228, 232, 236, 240, 244.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 569, 572, 575, 578.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a bare semicolon-separated list of the ER’s own risk names; the “⚠️ Conflicted” marker and all Magnitude text dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High and no Medium risk; both spans carry style="display: none" and the ER’s “No risk reaches High/Medium” sentences were correctly not carried over.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows map one-to-one to the ER biomarker table at lines 379–386.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers present with targets and rationales verbatim: serum magnesium, RBC magnesium, TSH, INR, tryptase, eGFR, LDL cholesterol, daily symptom score.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 688 condenses ER lines 373–375, retaining the two-week baseline, six-week TSH, one-to-two-week INR, six-to-twelve-month routine, and one-off allergist testing.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items map to the ER’s qualitative marker list at lines 390–394.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five present: digestive comfort, energy, cognitive clarity, skin, adherence and confidence.

Issues 26/08/2026 09:23

Pass rate 100.00%. No issues found.

Issues 26/08/2026 09:20

1. 1.1 / 1.3 — Half-life value contradicts ER: time_1_value at line 486 reads “3–5 hours” under the label “Expected half-life”, but ER line 308 states “No drug-like half-life applies” and gives three to five hours only as the peak time in fat-carrying blood particles.
2. 2.5 / 2.6 / 2.9 — Imperative addresses the reader: action_3_value at line 469 reads “Split a large stack”, an imperative recommendation directed at the reader, where the ER (line 310) states “Irrelevant for the excipient in isolation”.

Fixes 26/08/2026 09:20

1. 1.1 / 1.3 — Half-life value contradicts ER: Replaced time_1_value “3–5 hours” with “None applies” wording — now “No half-life applies” — and moved the three-to-five-hour figure into time_1_sub where the ER attaches it, to the peak in fat-carrying blood particles rather than to a half-life.
2. 2.5 / 2.6 / 2.9 — Imperative addresses the reader: Replaced the imperative action_3_value “Split a large stack” with the ER’s own descriptive phrasing “Irrelevant in isolation”, and rewrote action_3_sub to carry the splitting detail as a statement rather than an instruction.